Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (HDAC) inhibitors
View Patent ↗The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts and tautomers thereof. Compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. They are also useful for treating neurodegenerative diseases, mental retardation, 10 schizophrenia, inflammatory diseases, restenosis, immune disorders, diabetes, cardiovascular disorders and asthma.
1. A compound of formula I:
wherein:
a is 0, 1, 2 or 3;
b is 0, 1, 2 or 3;
c is 0, 1 or 2;
A is CH or N;
the X ring is a substituent on a carbon atom of the sulfur containing ring, and is C 6-10 aryl, a 5 membered heteroaromatic ring containing 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, not more than one heteroatom of which is O or S, a 6 membered heteroaromatic ring containing 1, 2 or 3 nitrogen atoms, or a 7-15 membered saturated, partially saturated or unsaturated heterocyclic ring containing 1, 2, 3 or 4 heteroatoms independently selected from N, O and S; optionally substituted by one or more halogen groups;
Y is a direct bond, —O—, >(C═O), >S(O) d , —NR 2 (C═O)— or —(C═O)NR 2 —;
d is 0, 1 or 2;
R 2 is hydrogen or C 1-6 alkyl;
Z is hydrogen, halogen, cyano, hydroxyl, C 1-6 alkyl, haloC 1-6 alkyl, C 1-6 alkoxy, nitro, N(R a ) 2 ; or a ring which is: C 3-6 cycloalkyl; C 6-10 aryl; a 5 or 6 membered saturated or partially saturated heterocyclic ring containing 1, 2 or 3 heteroatoms independently selected from N, O and S; a 5 membered heteroaromatic ring containing 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, not more than one heteroatom of which is O or S; a 6 membered heteroaromatic ring containing 1, 2 or 3 nitrogen atoms; or a 7-10 membered saturated, partially saturated or unsaturated heterocyclic ring containing 1, 2, 3 or 4 heteroatoms independently selected from N, O and S; any of which rings being optionally substituted by one or more groups independently selected from R 3 ;
each R a is independently hydrogen, C 1-6 alkyl, C 1-6 alkylcarbonyl or SO 2 R b ;
R b is C 1-6 alkyl, amino, C 1-6 alkylamino or di(C 1-6 alkyl)amino;
each R 3 is independently halogen, cyano, oxo, hydroxyl, C 1-6 alkyl, haloC 1-6 alkyl, C 1-6 alkoxy, mercaptoC 1-6 alkyl, haloC 1-6 alkoxy, nitro, N(R a ) 2 , SO 2 R b , OSO 2 R b , COR c , C 1-6 alkylSO 2 R b , R d , C 1-6 alkylR d , C 1-6 alkoxyR d or C 1-6 alkoxySO 2 R d ;
R c is hydrogen, C 1-6 alkyl or C 1-6 alkoxy;
R d is C 6-10 aryl; a 5-membered heteroaromatic ring containing 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, not more than one heteroatom of which is O or S, or a 6 membered heteroaromatic ring containing 1, 2 or 3 nitrogen atoms; any of which rings being optionally substituted by one or more groups independently selected from halogen, C 1-6 alkyl, C 1-6 alkoxy, mercaptoC 1-6 alkyl, haloC 1-6 alkyl, haloC 1-6 alkoxy, amino, C 1-6 alkylamino and di(C 1-6 alkyl)amino;
providing that:
when A is CH and X is phenyl, then (CH═CH) c (CH 2 ) b —Y—(CH 2 ) a —Z is not hydrogen;
or a pharmaceutically acceptable salt or tautomer thereof.
2. The compound of claim 1 of formula II:
wherein a, b, c, X, Y and Z are as defined in claim 2 ;
provided that when X is phenyl, then (CH═CH) c (CH 2 ) b —Y—(CH 2 ) a —Z is not hydrogen;
or a pharmaceutically acceptable salt or tautomer thereof.
3. The compound of claim 2 of formula III:
wherein a, b, c, X, Y and Z are as defined in claim 3 ;
provided that when X is phenyl, then (CH═CH) c (CH 2 ) b —Y—(CH 2 ) a —Z is not hydrogen;
or a pharmaceutically acceptable salt or tautomer thereof.
4. The compound of claim 3 of formula IV:
wherein X and Z are as defined in claim 4 ;
provided that when X is phenyl, then Z is not hydrogen;
or a pharmaceutically acceptable salt or tautomer thereof.
5. The compound of claim 1 of formula V:
wherein:
X is C 6-10 aryl, a 5 membered heteroaromatic ring containing 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, not more than one heteroatom of which is O or S, a 6 membered heteroaromatic ring containing 1, 2 or 3 nitrogen atoms, or a 7-15 membered saturated, partially saturated or unsaturated heterocyclic ring containing 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, optionally substituted by one or more halogen groups; and
W is hydrogen, halogen, haloC 1-6 alkyl, cyano, nitro, C 1-6 alkoxy, C 1-6 alkylcarbonyl, C 6-10 aryl or C 6-10 aryloxy;
or a pharmaceutically acceptable salt or tautomer thereof.
6. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt or tautomer thereof and a pharmaceutically acceptable carrier.
7. The compound of claim 1 that is 3-[5-(Trifluoroacetyl)-2-thienyl]benzoic acid or a pharmaceutically acceptable salt thereof.
8. The compound of claim 1 that is 4-[5-(Trifluoroacetyl)-2-thienyl]benzoic acid or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition comprising a compound of claim 7 , or a pharmaceutically acceptable salt and a pharmaceutically acceptable carrier.
10. A pharmaceutical composition comprising a compound of claim 8 , or a pharmaceutically acceptable salt and a pharmaceutically acceptable carrier.